Jacobio Pharmaceuticals Group Co Ltd

Jacobio Pharmaceuticals Group Co Ltd maintains a strong liquidity position, with a current ratio of 5.1, indicating that it has more than five times the current assets to cover its current liabilities. The company's cash and equivalents amount to CNY 373.8 million, which is a significant portion of its total assets of CNY 1.3 billion. However, the company's liquidity is not supported by positive operating cash flow, as it reported an operating cash flow of -CNY 211.0 million in the latest period.

In terms of profitability, Jacobio Pharmaceuticals Group Co Ltd is currently unprofitable, with a net loss of CNY 145.98 million and an operating loss of CNY 164.75 million. The company's return on equity is -18.94%, and its return on assets is -11.19%, both of which are significantly below the industry median for biotechnology firms. The company's gross profit margin is 99.8%, which is high, but this is offset by substantial operating expenses that result in a negative operating margin.

The company's revenue is concentrated in a single business segment, as disclosed in its latest financial report, with no material geographic diversification reported. This lack of diversification may expose the company to higher risk if its primary market or product line experiences a downturn.

Looking ahead, Jacobio Pharmaceuticals Group Co Ltd is expected to continue its current trajectory of negative operating and net income, with no significant changes in revenue or profitability expected in the near term. The company's capital expenditures are relatively low, with a capex of -CNY 1.67 million, suggesting that it is not heavily investing in new facilities or equipment. However, the company's long-term debt of CNY 165.17 million may require future refinancing or repayment, which could impact its liquidity.

The company's risk profile is characterized by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow suggest that it may need to raise additional capital in the future, which could lead to dilution for existing shareholders. The company's debt-to-equity ratio of 0.21 is relatively low, indicating that it is not heavily leveraged.

Recent events, including analyst estimates and recommendations, suggest that the market has a neutral outlook on the company. The mean price target is CNY 9.74, with a median of the same amount, and the mean recommendation is 3.00, indicating a "hold" rating. There are no strong buy or buy recommendations, which may reflect the company's current financial performance and the risks associated with its business model.